(Q34564295)

3 August 2017

1 reference

title

Telithromycin: the first of the ketolides (English)

1 reference

3 August 2017

Christopher S Shain

1

1 reference

3 August 2017

Guy W Amsden

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

Annals of Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

36

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

452-464

1 reference

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

3 August 2017

cites work

1 reference

Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens

21 January 2018

1 reference

Novelties in the field of anti-infectives in 1997.

21 January 2018

1 reference

New research in macrolides and ketolides since 1997.

21 January 2018

1 reference

Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage

21 January 2018

1 reference

Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates.

21 January 2018

1 reference

In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

21 January 2018

1 reference

In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria.

21 January 2018

1 reference

The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.

21 January 2018

1 reference

In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae

21 January 2018

1 reference

In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan

21 January 2018

1 reference

In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4

21 January 2018

1 reference

In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae

21 January 2018

1 reference

Activities of antimicrobial agents against intracellular pneumococci

21 January 2018

1 reference

Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila

21 January 2018

1 reference

In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials

21 January 2018

1 reference

In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, an

21 January 2018

1 reference

Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics

21 January 2018

1 reference

Postantibiotic suppression of growth of erythromycin A-susceptible and -resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004

21 January 2018

1 reference

Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1A038

1 reference

3 August 2017

1 reference